First-Pass Metabolism of THC
Why edibles produce different effects than smoking through hepatic metabolism of THC.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
When you eat THC, your liver transforms it into 11-hydroxy-THC before it reaches your brain — this is first-pass metabolism. That metabolite is also psychoactive, which is why edibles produce a longer, sometimes more intense, and unpredictable effect than smoking. It's not mystical; it's basic pharmacology. Your genetics, what you ate, and your medications all shift how much THC and metabolite actually circulate.
Plain-Language Summary
When you swallow THC, it doesn't go straight to your bloodstream. It gets absorbed from your gut and then travels through your liver before reaching general circulation. Your liver treats it like any other foreign chemical and starts breaking it down immediately. This is called first-pass metabolism.
Two important things happen:
- A large fraction of the swallowed THC is destroyed or transformed before it can reach your brain, reducing its potency. Oral bioavailability is approximately 4–20%, compared to 10–35% for inhaled THC Strong evidence[1][2].
- Much of what survives gets converted into 11-hydroxy-THC (11-OH-THC), which is also psychoactive Strong evidence[3][4].
Inhaled THC skips this process entirely. It goes from lungs to bloodstream to brain in seconds, and 11-OH-THC is produced in much smaller amounts Strong evidence[3].
This pharmacokinetic difference is why edibles take longer to kick in, last much longer, produce variable effects between individuals, and are easy to overdose on accidentally.
> This article is educational only and is not medical advice. It describes the pharmacology of THC metabolism, not treatment guidance. Talk to a clinician before using cannabis medicinally, especially if you take other medications.
What's Happening in Your Body
After you swallow THC, it is absorbed slowly and unevenly from your small intestine. Because THC is highly lipophilic (fat-soluble), absorption depends heavily on food, especially fat content Strong evidence[1][2].
Once absorbed, THC travels through the portal vein directly to your liver. There, enzymes called CYP2C9 and CYP3A4 chemically modify it at the 11 position, converting it to 11-OH-THC Strong evidence[4][5].
11-OH-THC is then further broken down into 11-nor-9-carboxy-THC (THC-COOH), which is inactive but is what drug tests detect Strong evidence[3].
Key points:
- 11-OH-THC binds the same CB1 receptor as THC and produces cannabis-like psychoactive effects in humans Strong evidence[4][6].
- After eating THC, blood levels of 11-OH-THC can equal or exceed those of parent THC. After smoking, 11-OH-THC is a small fraction of THC Strong evidence[3].
- Your genes matter. People with certain genetic variants in CYP2C9 (especially CYP2C9\3*) are "poor metabolizers" and show three times higher THC exposure after eating edibles Strong evidence[5].
- Common medications and foods can shift THC levels. Compounds that inhibit CYP3A4 (like ketoconazole and grapefruit) or induce it (like rifampin and St. John's wort) alter how much THC stays in your body, though real-world impact on typical edible use is unclear Weak / limited[7].
What the Evidence Clearly Shows
- Oral THC has low and unpredictable absorption (~4–20% of dose enters the bloodstream), much lower than inhaled (~10–35%) Strong evidence[1][2].
- 11-OH-THC is psychoactive in humans and produces cannabis-like subjective effects Strong evidence[6].
- Eating THC produces much more 11-OH-THC relative to parent THC than smoking does Strong evidence[3].
- Onset is delayed (typically 30–120 minutes after eating) and duration is longer (4–8 or more hours) compared to smoking Strong evidence[2].
- Your CYP2C9 genotype meaningfully affects how much THC and 11-OH-THC circulate after oral dosing Strong evidence[5].
- Delayed onset is the leading cause of accidental overdose with edibles; people redose before the first dose takes effect, leading to very high peak blood levels Strong evidence[8].
What Might Be True (Limited Evidence)
- "11-OH-THC is 2–3 times more potent than THC." This claim is often repeated online and in some reviews, but modern controlled human studies directly comparing equal doses of THC and 11-OH-THC are rare. The evidence supports that 11-OH-THC binds CB1 receptors similarly to THC and produces psychoactive effects, but calling it "much more potent" overstates what we know. A more accurate statement: 11-OH-THC is similarly potent, possibly somewhat more potent Weak / limited[4][6].
- Fatty meals dramatically increase edible strength. Fat clearly increases absorption of THC in animal studies and small human trials, but exactly how much it changes the effect of a typical edible in real life is not well defined Weak / limited[9].
- Sublingual (under-the-tongue) products "bypass" first-pass metabolism. They partially can, but many consumer sublingual tinctures are actually swallowed, resulting in first-pass metabolism like a regular edible. Prescription buccal products (like nabiximols) do reduce first-pass effect, but the fraction absorbed under the tongue vs. swallowed in typical consumer products is often uncertain Weak / limited[10].
- Drug-drug interactions via CYP3A4 and CYP2C9 produce major clinical effects. Plausible and shown in pharmacokinetic studies, but outcome data in real-world cannabis users are limited Weak / limited[7].
What Doesn't Hold Up
- "Edibles produce a fundamentally different high because they hit different brain receptors." False. Edibles and smoked cannabis activate the same receptors, primarily CB1. The difference is the pharmacokinetics (how fast and high the blood levels go) and the metabolite mix (more 11-OH-THC), not new targets Strong evidence[3][4].
- "Indica edibles are more sedating than sativa edibles." The indica vs sativa distinction does not reliably predict effects. Additionally, once THC is metabolized to 11-OH-THC by your liver, the terpenes and other compounds in the original flower have minimal bearing on the systemic psychoactive effect Disputed.
- "You cannot overdose on edibles; just wait it out." You cannot die from a cannabis overdose, but severe acute reactions—panic attacks, racing heart, vomiting, psychosis-like states, cannabinoid hyperemesis—are well documented and are driven largely by very high blood levels of THC and 11-OH-THC that result from delayed onset and redosing Strong evidence[8].
What We Still Don't Know
- How much 11-OH-THC vs. parent THC drives the subjective experience for a typical person eating an edible.
- Whether CYP2C9 or CYP3A4 genotyping could predict a person's individual edible response reliably enough to guide dosing in practice.
- Whether other commonly used compounds—CBD, other cannabinoids, alcohol, SSRIs, or other drugs—meaningfully alter first-pass THC metabolism at doses people actually consume.
- The specific dose-response relationship for adverse events (panic, tachycardia, psychosis) driven by 11-OH-THC.
- How much variation in edible potency stems from the cannabis source itself versus absorption and metabolism in the individual user.
How This Compares to Other Drugs
First-pass metabolism of THC is not unusual—it's the same process that makes oral morphine less potent than IV morphine, or that requires much higher oral doses of propranolol (a beta-blocker) than intravenous doses. What is unusual about THC is that the primary metabolite produced by the liver (11-OH-THC) is itself strongly psychoactive. So first-pass doesn't just reduce potency; it changes the effect profile.
Comparison:
- Oral morphine: First pass reduces total potency. The main metabolites (morphine-3-glucuronide, morphine-6-glucuronide) contribute little to acute analgesia.
- Oral codeine: First pass is actually necessary for the drug to work. The enzyme CYP2D6 must convert codeine to morphine. Genetic variation in CYP2D6 means some people get almost no effect and others get extreme effects.
- Oral THC: First pass reduces total potency and generates an active metabolite (11-OH-THC) comparable in effect to THC itself. Genetic variation in CYP2C9 moderately shifts exposure.
This is why "just take the same dose orally" is unreliable advice when switching between smoking and eating cannabis.
Risks and Practical Implications
Delayed onset drives accidental overdose. The most common reason people visit emergency departments after edible use is unintended overconsumption. Because edibles take 30–120 minutes to produce noticeable effects, users often redose before the first dose takes effect, resulting in very high peak blood concentrations Strong evidence[8]. Waiting at least 2 hours before taking more is essential.
High individual variability. The same dose produces wildly different effects across people due to genetics (CYP2C9 variants), body weight and composition, tolerance, gut contents, and co-medications Strong evidence[5]. A dose that is mild for one person can be incapacitating for another.
Drug interactions are possible. If you take medications metabolized by CYP3A4 or CYP2C9—including some SSRIs, warfarin, certain antifungals, some seizure medications—oral THC exposure can increase or decrease. Discuss potential interactions with a pharmacist Weak / limited[7]. See Cannabis and Polypharmacy Risks for more detail.
Accidental pediatric exposure is a concern. Edibles often resemble candy or snacks. When children unintentionally ingest them, they experience the same first-pass-driven surge of 11-OH-THC with a much lower body weight, leading to severe effects. Store edibles securely and out of reach. If a child ingests an edible, seek urgent medical attention or call poison control Strong evidence[8].
Uncertainty about effects. Because both THC and 11-OH-THC circulate and their relative contributions to subjective experience are unclear, individual responses to the same edible can be difficult to predict.
Bottom Line
First-pass metabolism is why eating cannabis is fundamentally different from smoking it. Your liver converts THC into 11-OH-THC, an active metabolite that can reach or exceed the blood level of THC itself. This slow, variable absorption and high metabolite production explain the delayed onset, longer duration, and unpredictability of edibles.
Genetics, food, medications, and body composition all shift how much active drug reaches your brain. There is no reliable formula to convert a smoking dose to an eating dose. Start low and wait long (at least 2 hours) before redosing. If you use cannabis medically or regularly take other medications, discuss oral cannabis with a clinician.
> Reminder: This is educational information, not medical advice. Do not use it to self-diagnose, self-treat a medical condition, or adjust prescribed medications. Consult a qualified healthcare provider before using cannabis medicinally or if you have questions about drug interactions.
Sources
- Peer-reviewed Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360.
- Peer-reviewed Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770–1804.
- Peer-reviewed Schwilke, E. W., Schwope, D. M., Karschner, E. L., Lowe, R. H., Darwin, W. D., Kelly, D. L., Goodwin, R. S., Gorelick, D. A., & Huestis, M. A. (2009). Δ9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clinical Chemistry, 55(12), 2180–2189.
- Peer-reviewed Watanabe, K., Yamaori, S., Funahashi, T., Kimura, T., & Yamamoto, I. (2007). Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sciences, 80(15), 1415–1419.
- Peer-reviewed Zgair, A., Wong, J. C., Lee, J. B., et al. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research, 8(8), 3448–3459.
- Peer-reviewed Sachse-Seeboth, C., Pfeil, J., Sehrt, D., Meineke, I., Tzvetkov, M., Bruns, E., Poser, W., Vormfelde, S. V., & Brockmöller, J. (2009). Interindividual variation in the pharmacokinetics of Δ9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clinical Pharmacology & Therapeutics, 85(3), 273–276.
- Peer-reviewed Lemberger, L., Crabtree, R. E., & Rowe, H. M. (1972). 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science, 177(4043), 62–64.
- Peer-reviewed Stott, C. G., White, L., Wright, S., Wilbraham, D., & Guy, G. W. (2013). A phase I study to assess the effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of a single dose of nabiximols oromucosal spray in healthy volunteers. European Journal of Clinical Pharmacology, 69(4), 825–834.
- Peer-reviewed Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A. (2011). Subjective and physiological effects after controlled Sativex and oral THC administration. Clinical Pharmacology & Therapeutics, 89(3), 400–407.
- Peer-reviewed Monte, A. A., Shelton, S. K., Mills, E., et al. (2019). Acute illness associated with cannabis use, by route of exposure: an observational study. Annals of Internal Medicine, 170(8), 531–537.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Choosing Your First Strain — A practical guide to picking a cannabis cultivar that matches your space, skill, and goals...
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...